Fenbendazole Cancer Biomarker Map: A Mechanistic Framework Linking TP53, MDM2/MDMX, KRAS, MYC, Cell-Cycle Regulators and Tumor Metabolism
Evidence review and hypothesis-generating biomarker framework
Abstract
Background: Fenbendazole is a benzimidazole anthelmintic used in veterinary medicine that has attracted interest as a potential repurposed anticancer compound. Preclinical studies have reported multiple biological effects, including disruption of microtubules, proteasome-associated stress, altered glucose utilization, effects on glycolysis, apoptosis, and changes in p53 signaling. However, fenbendazole is not an established human anticancer therapy, and human pharmacokinetic, efficacy, dosing, interaction, and safety data remain limited.
Objective: To develop a molecularly stratified framework for evaluating potential fenbendazole sensitivity according to tumor genotype and phenotype, with particular attention to TP53, MDM2, MDM4/MDMX, KRAS, EGFR, MYC, BRAF, RB1, CDKN2A, GLUT1, and HK2.
Methods: Published experimental and clinical literature was reviewed with emphasis on mechanistic studies, genotype-associated experiments, translational studies, animal models, and human safety reports. Evidence was classified using a four-level framework: A, direct fenbendazole biomarker evidence; B, strong preclinical mechanistic support; C, biological rationale or indirect evidence; and D, no meaningful fenbendazole-specific evidence sufficient to support a predictive biomarker claim.
Results: The strongest fenbendazole-specific biomarker hypothesis involves tumors retaining wild-type p53 in which p53 activity is suppressed by MDM2 and/or MDM4/MDMX overexpression. In melanoma and breast-cancer models, fenbendazole increased p53 and p21 while decreasing MDM2 and MDMX. Independent studies have reported effects on glucose uptake, GLUT transporters and HK2, providing a parallel metabolic mechanism. A drug-library study identified selective activity of benzimidazole derivatives, including fenbendazole, in KRAS-mutant lung-cancer models. MYC-associated effects have been reported in leukemia models. By contrast, evidence supporting EGFR, BRAF, RB1, or CDKN2A as predictive fenbendazole biomarkers remains insufficient.
Conclusions: Fenbendazole is best viewed as a multi-pathway experimental compound rather than a validated single-target anticancer agent. The most rational biomarker hypotheses are TP53-wild-type tumors with excessive MDM2/MDMX-mediated suppression and tumors with metabolic dependence involving GLUT/HK2, with KRAS-mutant NSCLC representing another notable preclinical signal. These hypotheses require formal biomarker-stratified studies before they can be translated into patient selection or treatment recommendations.
Keywords: fenbendazole; cancer biomarkers; TP53; p53; MDM2; MDM4; MDMX; KRAS; MYC; HK2; GLUT1; glycolysis; drug repurposing; precision oncology; metabolic oncology.
Clinical status and safety warning: Fenbendazole is a veterinary anthelmintic and is not approved by the U.S. FDA or European Medicines Agency as a human cancer treatment. A 2024 review concluded that human pharmacokinetic and safety data remain insufficient and that clinical trials are needed. Published case reports in 2021, 2024, and 2026 describe clinically important liver injury associated with self-administration. Fenbendazole should therefore not be presented as a proven cancer treatment or as a substitute for evidence-based oncology care. [5]
1. Introduction
Precision oncology increasingly recognizes that the biological behavior of a cancer cannot be adequately described by histologic diagnosis alone. Two tumors arising in the same organ may differ substantially in oncogenic drivers, tumor suppressor function, metabolism, drug resistance, immune microenvironment, and dependence on particular cellular pathways.
This principle is especially relevant to investigational drug repurposing. A compound that demonstrates cytotoxicity across several laboratory models does not necessarily have a universal mechanism of action. Conversely, a modest signal in an unselected population may become more interesting if a molecularly defined subgroup possesses a specific vulnerability.
Fenbendazole provides an illustrative example. Experimental research has associated the compound with several overlapping effects rather than a single validated molecular target. These include altered microtubule behavior, proteasome-associated stress, endoplasmic-reticulum stress, oxidative stress, altered glucose uptake, reduced glycolytic activity, and changes in p53 signaling. [2]
The most distinctive molecular observation concerns the p53 regulatory network. In a 2019 study, benzimidazoles including fenbendazole increased p53 activity and p21 while decreasing MDM2 and MDMX in melanoma and breast-cancer models with increased expression of these negative p53 regulators. The investigators interpreted these findings as promotion of wild-type p53 stability and transcriptional activity through downregulation of p53-negative regulators. [1]
This observation raises an important precision-oncology question:
The hypothesis is attractive, but it must not be confused with clinical validation. There is currently no established clinical biomarker demonstrating that patients with MDM2 amplification, MDMX overexpression, KRAS mutation, HK2 expression, or any other listed molecular characteristic benefit from fenbendazole.
2. Aims and Scope of the Biomarker Framework
The purpose of this review is not to recommend fenbendazole treatment. Instead, it is to organize the existing experimental evidence into a framework that can be tested scientifically.
The framework addresses five questions:
- Does the tumor retain potentially functional wild-type p53?
- Is p53 being suppressed by MDM2, MDM4/MDMX, or another regulatory mechanism?
- Does the tumor possess an oncogenic dependency such as KRAS activation?
- Does the tumor demonstrate metabolic dependence involving glucose transport or HK2?
- Could fenbendazole-associated cytotoxicity occur independently of the p53 pathway through microtubule, proteasome, oxidative-stress, or cell-cycle mechanisms?
3. Evidence-Grading Framework
| Grade | Definition | How it should be used |
|---|---|---|
| A | Direct fenbendazole-specific experimental evidence connecting the biomarker or genotype with a molecular response. | Strong preclinical signal; not evidence of clinical efficacy. |
| B | Strong mechanistic evidence involving fenbendazole and a pathway that is biologically relevant to the biomarker. | Promising translational hypothesis requiring genotype-selected validation. |
| C | Indirect pathway rationale, limited experiments, or evidence primarily involving related compounds. | Exploratory hypothesis only. |
| D | No convincing fenbendazole-specific evidence supporting the biomarker as predictive. | Do not present as a fenbendazole response biomarker. |
Important: Evidence grade refers to the strength of the fenbendazole-biomarker relationship, not the overall clinical validity of the drug. Even an A-grade preclinical association does not establish human efficacy.
4. Master Fenbendazole Biomarker Map
| Biomarker / phenotype | Potential relationship to fenbendazole | Priority cancer context | Grade | Current interpretation |
|---|---|---|---|---|
| TP53 wild-type | Potential p53 stabilization/activation | Melanoma, breast cancer, selected solid tumors | A | Strongest p53-dependent hypothesis |
| TP53 mutant | Possible p53-independent cytotoxicity; p53 reactivation uncertain | NSCLC, breast, colorectal and others | C | Mutation should not be interpreted as evidence of p53 restoration |
| TP53 null/deleted | p53-mediated branch is biologically compromised | Any cancer | D for p53 mechanism | Shift analysis toward non-p53 pathways |
| MDM2-high / amplified + TP53-WT | Potential reduction of MDM2-mediated p53 suppression | Sarcoma and other MDM2-driven tumors | A/B | High-priority research subgroup |
| MDM4/MDMX-high + TP53-WT | Potential release of p53 transcriptional activity | Melanoma, breast cancer | A | Directly aligned with published mechanistic work |
| KRAS-mutant | Selective cytotoxicity and suppression of RAS-related signaling reported in lung-cancer models | NSCLC | A | Important genotype-specific preclinical lead |
| EGFR-mutant | No convincing evidence that EGFR genotype independently predicts FBZ response | EGFR-driven NSCLC | D/C | Hypothesis only |
| MYC-high | MYC-associated transcriptional effects reported | Leukemia and MYC-driven tumors | B | Promising but unvalidated as predictive biomarker |
| BRAF-mutant | Pathway overlap is not sufficient to establish genotype sensitivity | Melanoma, colorectal cancer | D/C | Not a validated FBZ biomarker |
| RB1 loss | Cell-cycle biology could modify vulnerability to mitotic stress | SCLC, neuroendocrine cancers | D/C | Exploratory only |
| CDKN2A loss | Potential interaction with cell-cycle vulnerability | Melanoma, pancreatic cancer, NSCLC | D/C | Insufficient direct FBZ data |
| GLUT1/high glucose uptake | Reduced glucose uptake and GLUT-related expression reported | Metabolically glycolytic solid tumors | B | Important metabolic hypothesis |
| HK2-high | Reduced HK2 and glycolytic activity; cell-death signaling | Breast cancer, NSCLC | A/B | High-priority metabolic biomarker hypothesis |
5. TP53: The Central Decision Point
5.1 Why TP53 Matters in Cancer
Few genes have had a greater influence on modern cancer biology than TP53. The gene was identified in 1979 and was initially misunderstood because early experiments included mutant forms of p53 that appeared to promote tumor formation. Subsequent research established that normal, or wild-type, p53 is a major tumor suppressor.
TP53 is altered in roughly 50% of human cancers, although the exact frequency varies substantially by cancer type. Some tumors contain TP53 mutations, while others disable the pathway through alterations in regulators such as MDM2 or through other mechanisms that suppress p53 activity.
This distinction is important: TP53 mutation is not synonymous with complete loss of p53 function, and not every TP53 alteration has the same biological or therapeutic consequences.
Key concept: TP53 should be viewed not simply as a “DNA repair gene,” but as a stress-response system that helps determine whether a damaged cell repairs itself, stops dividing, enters senescence or undergoes programmed cell death.
Few genes have had a greater influence on modern cancer biology than TP53. The gene was identified in 1979 and was initially misunderstood because early experiments included mutant forms of p53 that appeared to promote tumor formation. Subsequent research established that normal, or wild-type, p53 is a major tumor suppressor.
TP53 is altered in roughly 50% of human cancers, although the exact frequency varies substantially by cancer type. Some tumors contain TP53 mutations, while others disable the pathway through alterations in regulators such as MDM2 or through other mechanisms that suppress p53 activity.
This distinction is important: TP53 mutation is not synonymous with complete loss of p53 function, and not every TP53 alteration has the same biological or therapeutic consequences.
Key concept: TP53 should be viewed not simply as a “DNA repair gene,” but as a stress-response system that helps determine whether a damaged cell repairs itself, stops dividing, enters senescence or undergoes programmed cell death.
5.2 TP53 and p53: What Is the Difference?
TP53 is the gene. p53 is the protein encoded by that gene.
In molecular oncology, the terms are often used interchangeably in casual discussion, but they describe different biological entities. TP53 mutations can alter the amount, structure, stability, DNA-binding capacity or regulatory behavior of the resulting p53 protein.
The p53 protein is a transcription factor containing several functional regions, including a transactivation domain, DNA-binding domain, tetramerization domain and regulatory C-terminal region. The DNA-binding region is particularly important because many cancer-associated mutations interfere with p53's ability to regulate downstream genes.
TP53 is the gene. p53 is the protein encoded by that gene.
In molecular oncology, the terms are often used interchangeably in casual discussion, but they describe different biological entities. TP53 mutations can alter the amount, structure, stability, DNA-binding capacity or regulatory behavior of the resulting p53 protein.
The p53 protein is a transcription factor containing several functional regions, including a transactivation domain, DNA-binding domain, tetramerization domain and regulatory C-terminal region. The DNA-binding region is particularly important because many cancer-associated mutations interfere with p53's ability to regulate downstream genes.
5.3 TP53 Wild-Type
Evidence grade: A
The clearest p53 hypothesis applies to tumors retaining wild-type TP53. The central concept is not simply “p53-positive cancer,” but rather functional p53 that is suppressed by regulatory mechanisms.
In the 2019 melanoma and breast-cancer study, fenbendazole treatment increased p53 and p21 and reduced MDM2 and MDMX. The study therefore provides direct preclinical evidence for a fenbendazole-associated p53 response in cellular models in which wild-type p53 was restrained by elevated negative regulators. [1]
This creates the most plausible biomarker-enrichment strategy for future investigation: identify tumors that retain wild-type TP53 but exhibit unusually high MDM2, MDM4/MDMX, or related p53-suppressive signaling.
5.4 TP53 Mutant
Evidence grade: C for the p53-reactivation hypothesis
TP53 mutation requires a fundamentally different interpretation. Reducing MDM2 or MDMX does not automatically restore a defective mutant p53 protein to normal tumor-suppressor function.
Therefore:
TP53-mutant ≠ p53-reactivated.
Nevertheless, a TP53-mutant cancer could theoretically remain susceptible to fenbendazole through non-p53 mechanisms. Laboratory studies have reported microtubule disruption, proteasome-associated stress, oxidative stress, altered mitochondrial signaling and metabolic effects. [2]
5.5 TP53 Null or Deleted
Evidence grade: D for the MDM2/MDMX→p53 mechanism
If TP53 is absent, an MDM2/MDMX-mediated p53 reactivation mechanism cannot function in the conventional manner. Such cancers would therefore have to be studied primarily through fenbendazole's non-p53 mechanisms.
6. MDM2 and MDM4/MDMX: The Most Important Regulatory Pair
6.1 MDM2-High or MDM2-Amplified, TP53-Wild-Type Tumors
Evidence grade: A/B
MDM2 is a central negative regulator of p53. Excess MDM2 can suppress p53 activity even when the underlying TP53 gene remains wild-type.
This creates a biologically intriguing phenotype:
The published fenbendazole work demonstrated decreased Mdm2 in experimental tumor cells together with increased p53 and p21. [1]
However, a major distinction must be preserved: fenbendazole has not been clinically established as a selective MDM2 inhibitor. The experimental observation is better described as MDM2 downregulation or suppression associated with p53 activation.
Future work would need to compare MDM2-amplified/TP53-WT cells with MDM2-normal/TP53-WT controls and establish whether MDM2 status actually predicts selective fenbendazole sensitivity.
6.2 MDM4/MDMX-High, TP53-Wild-Type Tumors
Evidence grade: A
This phenotype is particularly interesting because it closely matches the biological context of the 2019 experiment. The investigators selected benzimidazole compounds in a melanoma model with elevated MdmX and found increased p53 activity with reduced Mdm2 and MdmX. [1]
A future biomarker study could therefore stratify:
and determine whether the first subgroup exhibits a reproducibly larger pharmacodynamic response.
7. KRAS: A Second Major Preclinical Signal
Evidence grade: A for genotype-specific preclinical evidence in lung cancer
KRAS is one of the major oncogenic drivers in non-small-cell lung cancer. A drug-library screen involving 1,271 compounds compared KRAS-mutant and KRAS-wild-type lung-cancer cell lines and identified benzimidazole derivatives, including fenbendazole, among compounds with selective cytotoxic effects in KRAS-mutant models. The study also reported suppression of RAS-related signaling in KRAS-mutated cells. [4]
This makes KRAS-mutant NSCLC one of the highest-priority genotype-specific hypotheses for future investigation.
However, this should not be translated into the statement “fenbendazole targets KRAS.” The experimental data indicate differential activity and signaling effects, not selective direct inhibition of the KRAS protein itself.
8. KRAS, TP53 and Metabolism: A Potential Convergence Phenotype
A particularly interesting research direction emerges when oncogenic signaling and tumor metabolism are considered together.
Independent experimental work has shown that fenbendazole can reduce glucose uptake, alter GLUT transporter expression and suppress hexokinase II activity in NSCLC models. [2]
Because KRAS-driven tumors can have substantial metabolic dependence, the following composite phenotype deserves investigation:
This is a hypothesis-generating convergence model. It has not been demonstrated in prospective human cancer studies.
9. EGFR
Evidence grade: D/C
EGFR is a major therapeutic driver in NSCLC, but current evidence does not justify treating EGFR mutation as an established fenbendazole biomarker.
There is an important difference between pathway interaction and genotype-specific therapeutic dependence. Evidence that a compound changes a downstream signaling pathway is not sufficient to conclude that patients with a specific EGFR mutation will preferentially respond.
Accordingly, EGFR should currently appear on a fenbendazole biomarker map as an exploratory variable, not a validated selection biomarker.
10. MYC
Evidence grade: B
MYC is a central transcriptional regulator of proliferation, metabolism and cellular stress. Fenbendazole-associated changes in MYC have been reported in leukemia experiments, including transcriptomic/network analyses and experimental reduction of MYC expression. [15]
The current evidence supports an interesting hypothesis:
However, the field has not demonstrated that MYC amplification or protein abundance independently predicts fenbendazole sensitivity. MYC therefore remains a promising but unvalidated biomarker.
11. BRAF
Evidence grade: D/C
BRAF is particularly relevant to melanoma, where BRAF V600 alterations can activate the MAPK pathway. Because fenbendazole has been studied in melanoma and some experiments have reported changes in signaling networks, BRAF status may appear intuitively relevant.
However, pathway overlap is not equivalent to a genotype-response relationship. There is currently insufficient evidence to classify BRAF mutation as a predictive fenbendazole biomarker.
In a melanoma-focused biomarker strategy, TP53/MDM2/MDMX status has stronger direct fenbendazole support than BRAF status.
12. RB1
Evidence grade: D/C
RB1 is a central regulator of cell-cycle progression. Loss of RB1 can increase E2F activity and promote uncontrolled proliferation. Fenbendazole, meanwhile, has repeatedly been associated with G2/M disruption and mitotic abnormalities in experimental systems. [1]
This creates a biologically plausible question but not an established biomarker relationship:
Does RB1 loss increase or decrease sensitivity to fenbendazole-induced mitotic stress?
That question should be answered experimentally rather than assumed.
13. CDKN2A
Evidence grade: D/C
CDKN2A contributes to cell-cycle control through p16INK4A and the RB pathway. CDKN2A loss is common in several cancer types, including melanoma and pancreatic cancer.
Because fenbendazole can induce cell-cycle arrest, CDKN2A status may eventually prove useful for response stratification. At present, however, direct evidence linking CDKN2A loss to preferential fenbendazole sensitivity is inadequate.
14. GLUT1 and Tumor Glucose Dependence
Evidence grade: B
One of the most reproducible non-p53 themes in the fenbendazole literature is interference with tumor metabolism.
In NSCLC models, fenbendazole reduced glucose uptake and altered the expression of glucose transporters. The same study reported suppression of hexokinase II and effects consistent with disruption of glucose metabolism. [2]
The mechanistic implication is not that fenbendazole should be described as a conventional selective GLUT1 inhibitor. Rather, the drug appears capable of disturbing several parts of the tumor's metabolic system.
15. HK2: An Emerging Metabolic Biomarker
Evidence grade: A/B
HK2 may be one of the most interesting metabolic biomarkers in the current framework because it lies close to a major metabolic control point in glycolysis.
Recent breast-cancer research reported that fenbendazole inhibited glycolysis through HK2 downregulation and was associated with activation of caspase-3/GSDME-dependent pyroptotic signaling. The investigators also reported suppression of tumor growth in a mouse mammary-carcinoma model. [9]
The earlier NSCLC work also showed effects on glucose uptake and HKII. [2]
These findings support a testable hypothesis:
Whether baseline HK2 expression predicts clinical response remains unknown.
16. Fenbendazole Is Better Conceptualized as a Multi-Node Stressor
The combined literature argues against reducing fenbendazole's proposed anticancer activity to one molecular target.
Integrated Mechanistic Model
Experimental studies have reported several of these branches independently. Fenbendazole has been associated with moderate mammalian tubulin effects, glucose-uptake suppression, HKII changes, mitochondrial p53 translocation, proteasome inhibition, ER stress and reactive oxygen species. [2]
This multi-node model also explains why a simple “TP53-positive versus TP53-negative” classification is unlikely to fully predict response.
17. Cancer-Type Priority Map
| Cancer type | Potential biomarker priorities | Current evidence | Research priority |
|---|---|---|---|
| Melanoma | TP53-WT; MDM2-high; MDMX-high | Direct p53/MDM2/MDMX evidence | High |
| Breast cancer | TP53-WT; MDM2/MDMX; HK2-high | p53 and metabolic experimental evidence | High |
| NSCLC | KRAS-mutant; HK2-high; TP53 status | Multiple independent preclinical mechanisms | High |
| Sarcoma | MDM2-amplified + TP53-WT | Strong biological rationale; fenbendazole-specific validation lacking | High |
| Leukemia | MYC-high / proliferation phenotype | Transcriptomic and experimental evidence | Moderate |
| Ovarian cancer | Cell-cycle and metabolic phenotypes | In vitro/in vivo evidence; biomarker selection incomplete | Moderate |
| Cervical cancer | G2/M and cancer-stem-cell phenotypes | In vitro and xenograft evidence | Moderate |
| Colorectal cancer | TP53, KRAS, metabolism | Experimental rationale, limited biomarker specificity | Exploratory |
| Pancreatic cancer | KRAS; CDKN2A; HK2 | Strong cancer biology rationale, weak FBZ predictive evidence | Exploratory |
| Prostate cancer | RB1; MYC; metabolism | Insufficient predictive evidence | Exploratory |
| Glioblastoma | Microtubule/metabolic phenotype | Related benzimidazole literature; FBZ biomarker evidence limited | Exploratory |
Fenbendazole has also shown experimental anticancer effects in ovarian cancer and cervical cancer models, but the existence of tumor-growth effects does not itself establish a predictive biomarker. [2]
18. Composite Biomarker Phenotypes
A major advantage of a systems-biology approach is that tumors can be classified using combinations of biomarkers rather than one mutation at a time.
18.1 Phenotype A: p53 Suppression
TP53-WT + MDM2-high and/or MDMX-high
This is the strongest direct mechanistic hypothesis.
18.2 Phenotype B: KRAS–Glycolysis
KRAS-mutant + HK2-high + high glycolytic dependence
This phenotype combines the KRAS-specific lung-cancer signal with the metabolic literature.
18.3 Phenotype C: p53-Loss Metabolic Vulnerability
TP53 loss + KRAS activation + HK2-high
This phenotype may be particularly useful for testing whether fenbendazole's metabolic mechanisms can operate where p53 reactivation is unlikely.
18.4 Phenotype D: MYC-Driven Proliferation
MYC-high + high proliferative burden
This remains a secondary experimental phenotype because MYC-specific predictive evidence is less developed.
18.5 Phenotype E: Cell-Cycle Vulnerability
RB1 loss and/or CDKN2A loss
This should currently be treated as exploratory rather than predictive.
19. Biomarkers That Should Not Yet Be Described as Established Targets
| Claim | Recommended wording |
|---|---|
| “Fenbendazole targets MDM2.” | Fenbendazole has been associated with reduced MDM2 levels in experimental models. |
| “Fenbendazole is an MDM2 inhibitor.” | Not established; selective pharmacologic MDM2 inhibition has not been demonstrated clinically. |
| “Fenbendazole targets KRAS.” | Fenbendazole showed genotype-associated activity in KRAS-mutant lung-cancer models. |
| “Fenbendazole is an EGFR inhibitor.” | Not established. |
| “Fenbendazole is a BRAF inhibitor.” | Not established. |
| “TP53-mutant cancers respond to fenbendazole.” | Not established; p53-independent mechanisms remain under investigation. |
| “TP53 wild-type predicts response.” | TP53-WT provides a biologically plausible context for p53-dependent investigation, especially with MDM2/MDMX elevation. |
| “HK2-high cancers are clinically sensitive.” | HK2 is a promising experimental metabolic biomarker requiring clinical validation. |
20. Clinical Translation: What Evidence Is Missing?
The central translational problem is not whether fenbendazole can affect cancer cells in a laboratory. Multiple studies indicate that it can under experimental conditions. The harder questions are whether clinically achievable exposure produces reproducible antitumor effects in humans, which patients are most likely to benefit, what dose and formulation would be required, and whether the therapeutic window is acceptable.
A 2024 review emphasized that fenbendazole's human pharmacokinetic and safety profile remains poorly characterized and called for clinical trials evaluating efficacy, dosing, treatment schedules and tolerability. [5]
20.1 Biomarker validation study design
A rational preclinical program would test matched cell lines and organoids according to:
| Variable | Example stratification |
|---|---|
| TP53 | WT / missense mutant / null |
| MDM2 | Low / intermediate / amplified-high |
| MDM4/MDMX | Low / high |
| KRAS | WT / G12C / G12D / G12V / other |
| EGFR | WT / exon 19 deletion / L858R / other |
| MYC | Normal / amplified-high |
| BRAF | WT / V600E / other |
| RB1 | Intact / loss |
| CDKN2A | Intact / deleted or inactivated |
| GLUT/HK2 | Low / high expression or metabolic dependence |
Researchers could then measure IC50/IC90 relationships, p53 transcriptional activity, MDM2/MDMX protein levels, p21 induction, glucose uptake, HK2 activity, mitochondrial effects, mitotic arrest and apoptosis. The critical endpoint would be interaction between biomarker status and drug response, rather than response alone.
21. Potential Pharmacodynamic Biomarkers
If fenbendazole were ever tested prospectively in oncology, molecular pharmacodynamic measurements could be more informative than baseline genotype alone.
| Pathway | Potential pharmacodynamic marker |
|---|---|
| p53 | p53 protein, p53 transcriptional activity |
| Cell cycle | p21, G2/M arrest, mitotic abnormalities |
| MDM2/MDMX | Protein abundance before and after exposure |
| Glycolysis | Glucose uptake, lactate production, HK2 |
| Proteostasis | Proteasome activity, ER-stress markers |
| Oxidative stress | ROS-associated signaling |
| Mitochondria | Membrane potential, cytochrome-c signaling, mitochondrial p53 |
22. Human Evidence and the Importance of Negative Evidence
The gap between preclinical promise and human efficacy is substantial.
A 2021 case report described severe liver injury in an 80-year-old woman with advanced NSCLC who self-administered fenbendazole while receiving pembrolizumab. After fenbendazole was discontinued, liver dysfunction resolved; the report also noted no tumor shrinkage attributable to fenbendazole. [10]
A 2024 report described histologically confirmed severe drug-induced liver injury in a 67-year-old woman who had self-administered fenbendazole. Liver tests normalized after discontinuation. [11]
Newer 2026 reports have continued to document clinically significant fenbendazole-associated liver injury, including a case occurring during concomitant cancer immunotherapy. [13]
These safety observations do not disprove laboratory anticancer mechanisms. They demonstrate why mechanistic plausibility and human therapeutic benefit must be evaluated separately.
23. Retraction of a Frequently Cited Human Case Series
A three-patient 2025 case series describing self-administration of fenbendazole in patients with advanced cancer was subsequently retracted on January 21, 2026. The PubMed record now identifies the original article as a retracted publication and provides the formal retraction notice. The case series should therefore not be cited as positive clinical evidence for fenbendazole efficacy. [14]
This is a particularly important lesson for online cancer-information databases: case reports and patient narratives should be retained as records of reported observations when appropriate, but they should be clearly separated from validated clinical evidence, and retracted publications should never remain in a positive-evidence category.
24. Proposed Fenbendazole Precision-Oncology Knowledge Graph
A structured knowledge graph could represent fenbendazole evidence as:
For example:
A second record could be:
25. Research Priorities
Based on the current evidence, a rational experimental sequence would prioritize:
- TP53-WT + MDM2-high/MDMX-high tumors to determine whether the p53 pathway is genuinely predictive.
- KRAS-mutant NSCLC to reproduce and molecularly dissect genotype-associated sensitivity.
- HK2-high / glycolysis-dependent tumors to determine whether metabolic phenotype predicts response independently of TP53.
- Composite phenotypes such as KRAS-mutant + TP53-loss + HK2-high.
- MYC-high tumors as a secondary transcriptional vulnerability hypothesis.
- RB1/CDKN2A/BRAF/EGFR only after stronger direct evidence emerges.
26. Limitations
This framework has several important limitations.
First, much of the evidence comes from cell lines and animal models. Concentrations effective in vitro cannot automatically be translated into safe or achievable human exposure.
Second, fenbendazole has multiple proposed mechanisms, making causal attribution difficult. A reduction in tumor growth can occur without proving that MDM2/MDMX, p53, KRAS or HK2 was the primary driver.
Third, biomarker expression is dynamic. Tumors can evolve under treatment pressure, and protein abundance does not necessarily equal pathway dependence.
Fourth, tumor heterogeneity means that a single biopsy may fail to characterize every metastatic clone.
Fifth, most importantly, no biomarker in this framework has been validated prospectively as a clinical predictor of fenbendazole benefit.
27. Discussion
The central conceptual advance provided by this framework is a shift from asking whether “fenbendazole works in cancer” to asking which molecular states might make a tumor more or less vulnerable to the biological stresses associated with fenbendazole exposure.
Among the available hypotheses, the p53-regulatory axis stands out because there is direct experimental evidence connecting fenbendazole with reduced MDM2/MDMX and increased p53/p21 signaling in relevant tumor models. [1]
The metabolic axis provides a second compelling layer. Fenbendazole has been reported to reduce glucose uptake and HKII, while newer work has linked HK2 suppression to cancer-cell death. [2]
KRAS-mutant lung cancer provides a third important signal because a large compound screen identified genotype-associated effects of fenbendazole and related benzimidazoles. [4]
These observations do not establish fenbendazole as a precision-oncology drug. They establish a set of testable hypotheses that can be evaluated using modern models such as patient-derived organoids, genetically engineered cell systems, xenografts, transcriptomic profiling, phosphoproteomics, metabolic flux analysis and biomarker-stratified clinical studies.
28. Conclusion
Fenbendazole's experimental anticancer profile is best understood as multi-pathway rather than single-target. The strongest current biomarker hypothesis involves tumors with wild-type TP53 but excessive MDM2 and/or MDM4/MDMX-mediated suppression of p53. A second important hypothesis involves KRAS-mutant NSCLC, while a parallel metabolic hypothesis centers on GLUT/glucose dependence and HK2.
MYC remains an intriguing secondary signal. EGFR, BRAF, RB1 and CDKN2A should presently remain exploratory variables rather than claimed predictive biomarkers.
The resulting framework is therefore:
At present, these remain research hypotheses, not patient-selection rules. The absence of validated human efficacy data means fenbendazole should not replace standard cancer treatment. Its possible role in oncology can only be established through appropriately designed preclinical and clinical studies.
Patient-first interpretation: Molecular plausibility is not the same as proven clinical benefit. A cancer patient's treatment decisions should be based on the diagnosis, stage, pathology, molecular profile, standard-of-care options, clinical-trial availability, treatment goals, drug interactions, and safety considerations, ideally in consultation with the treating oncology team.
29. Evidence Summary at a Glance
| Biomarker | Current grade | Confidence in predictive value |
|---|---|---|
| TP53-WT | A | Promising preclinical context |
| MDM2-high / amplified + TP53-WT | A/B | High-priority research hypothesis |
| MDM4/MDMX-high + TP53-WT | A | Strong mechanistic hypothesis |
| KRAS-mutant NSCLC | A | Important genotype-specific preclinical signal |
| HK2-high | A/B | Important metabolic hypothesis |
| GLUT1/high glucose dependence | B | Promising mechanistic signal |
| MYC-high | B | Exploratory but interesting |
| TP53-mutant | C | p53-reactivation hypothesis weak |
| EGFR-mutant | D/C | Not established |
| BRAF-mutant | D/C | Not established |
| RB1 loss | D/C | Exploratory |
| CDKN2A loss | D/C | Exploratory |
30. References
- Mrkvová Z, Uldrijan S, Pombinho A, Bartůněk P, Slaninová I. Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells. Molecules. 2019;24(11):2152. DOI: 10.3390/molecules24112152. Full article.
- Dogra N, et al. Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Scientific Reports. 2018;8:11926. PMID: 30093705. PubMed.
- Dobashi Y, et al. Impairment of the ubiquitin-proteasome pathway by methyl N-(6-phenylsulfanyl-1H-benzimidazol-2-yl)carbamate leads to a potent cytotoxic effect in tumor cells. PMID: 22745125. PubMed.
- Yokoyama Y, et al. Drug library screen reveals benzimidazole derivatives as selective cytotoxic agents for KRAS-mutant lung cancer. PMID: 30862488. PubMed.
- Nguyen J, Nguyen TQ, Han BO, Hoang BX. Oral Fenbendazole for Cancer Therapy in Humans and Animals. Anticancer Research. 2024;44(9):3725-3735. DOI: 10.21873/anticanres.17197. PubMed.
- Jung H, Kim SY, Joo HG. Fenbendazole Exhibits Differential Anticancer Effects In Vitro and In Vivo in Models of Mouse Lymphoma. Current Issues in Molecular Biology. 2023;45(11):8925-8938. DOI: 10.3390/cimb45110560. PubMed.
- Chang CS, et al. Anti-cancer effect of fenbendazole-incorporated PLGA nanoparticles in ovarian cancer. Journal of Gynecologic Oncology. 2023;34(5):e58. DOI: 10.3802/jgo.2023.34.e58. PubMed.
- Wang X, et al. Transcriptome analysis reveals the anticancer effects of fenbendazole on ovarian cancer: an in vitro and in vivo study. BMC Cancer. 2024;24:1593. DOI: 10.1186/s12885-024-13361-9. PubMed.
- Pan H, et al. Fenbendazole induces pyroptosis in breast cancer cells through HK2/caspase-3/GSDME signaling pathway. PMID: 40756987. PubMed.
- Yamaguchi T, et al. Drug-Induced Liver Injury in a Patient with Nonsmall Cell Lung Cancer after the Self-Administration of Fenbendazole Based on Social Media Information. Case Reports in Oncology. 2021;14(2):886-891. DOI: 10.1159/000516276. PubMed.
- Thakurdesai A, et al. Severe Drug-Induced Liver Injury Due to Self-administration of the Veterinary Anthelmintic Medication, Fenbendazole. ACG Case Reports Journal. 2024;11(5):e01354. DOI: 10.14309/crj.0000000000001354. PubMed.
- Krishnan A, et al. Differentiating fenbendazole-induced liver injury from immunotherapy hepatitis - the importance of structured causality assessment: a case report. World Journal of Clinical Cases. 2026. DOI: 10.12998/wjcc.v14.i2.116700. PubMed.
- Satinsky A, Mayer N, Swanson C, Sasso B. Fenbendazole-Associated Drug-Induced Liver Injury with Concomitant Use of Tauroursodeoxycholic Acid. ACG Case Reports Journal. 2026;13(7):e02222. DOI: 10.14309/crj.0000000000002222. PubMed.
- Retraction Statement: Paper by William Makis, Ilyes Baghli, and Pierrick Martinez entitled “Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients”. Case Reports in Oncology. 2026;19(1):169. DOI: 10.1159/000549387. PubMed.
- Motamedi YK, et al. Transcriptional drug repositioning and cheminformatics approach for differentiation therapy of leukaemia cells. Scientific Reports. 2021. Nature
31. Medical Disclaimer
This article is an educational review of experimental biomedical literature. It does not constitute medical advice, a treatment recommendation, or a statement that fenbendazole is effective against cancer in humans. Fenbendazole is a veterinary anthelmintic and is not established as a human anticancer treatment. Preclinical findings may fail to translate into meaningful clinical benefit, and safety risks may be substantial. Patients with cancer should not delay, discontinue, or replace evidence-based treatment on the basis of laboratory studies, case reports, social-media claims, or this article.
Editorial evidence classification: Evidence grades in this article describe the strength of the available fenbendazole-specific biomarker evidence and should not be interpreted as regulatory approval, clinical efficacy ratings, or treatment recommendations.
.png)
.png)
Comments
Post a Comment